文献速递淋巴瘤

结节性淋巴细胞为主型霍奇金淋巴瘤HD7至HD15试验长期随访:德国霍奇金研究组报告

Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.
PubMed 文献 · J Clin Oncol · 2019-10-18

该回顾性分析基于德国霍奇金研究组(GHSG)HD7至HD15随机试验数据库,纳入471例初诊结节性淋巴细胞为主型霍奇金淋巴瘤(NLPHL)患者(早期251例、中期76例、晚期144例),接受分期适配的一线治疗。中位观察9.2年,10年无进展生存率和总生存率分别为75.5%和92.1%;48例(10.2%)发生第二恶性肿瘤,43例(9.1%)死亡,其中仅10例死亡与NLPHL相关。结论认为总体结局良好,但仍需优化治疗以降低标准风险患者毒性并改善高风险患者预后。

要点

  • NLPHL患者接受霍奇金淋巴瘤导向一线治疗后10年PFS为75.5%、OS为92.1%。
  • 第二恶性肿瘤发生率为10.2%,死亡主要归因于第二恶性肿瘤及非恶性疾病。
  • 仅少数死亡(10例)与NLPHL相关,提示需关注治疗远期毒性。

核心结论

  • 接受GHSG随机试验方案中霍奇金淋巴瘤导向一线治疗的NLPHL患者总体结局良好。
  • 仍需要优化治疗以降低标准风险患者的毒性并改善高风险患者的预后。

研究设计与样本

  • 回顾性分析基于德国霍奇金研究组(GHSG)数据库。
  • 纳入471例NLPHL患者,其中早期251例、中期76例、晚期144例。
  • 患者在接受随机GHSG HD7至HD15研究中接受分期适配的一线治疗,治疗包括单纯放疗、单纯化疗或联合模式。

主要发现

  • 诊断时中位年龄39岁(范围16至75岁),男性占75.8%,中位观察时间9.2年。
  • 10年无进展生存率和总生存率分别为75.5%和92.1%;早期分别为79.7%和93.3%,中期分别为72.1%和96.2%,晚期分别为69.8%和87.4%。
  • 48例(10.2%)在随访期间发生第二恶性肿瘤:非霍奇金淋巴瘤13例、白血病6例、实体瘤25例、未明确恶性肿瘤4例。
  • 43例(9.1%)死亡,其中仅10例死亡与NLPHL相关,20例死于第二恶性肿瘤,13例死于可能与放疗或化疗相关的非恶性疾病。

临床怎么用

  • NLPHL一线治疗后可获得较好的长期生存,但应重视第二恶性肿瘤及治疗相关非恶性疾病的远期风险。
  • 对标准风险患者需权衡治疗强度以降低毒性,对高风险患者需探索更有效策略以改善预后。

局限性

  • 为回顾性分析,基于GHSG HD7至HD15试验数据库,可能存在选择偏倚。
  • 中位观察时间9.2年,更长期随访数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The optimal treatment of newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is ill defined. We therefore conducted a retrospective analysis using the database of the German Hodgkin Study Group (GHSG). PATIENTS AND METHODS: The long-term course of 471 patients with NLPHL (early stages, n = 251; intermediate stages, n = 76; advanced stages, n = 144) who had received stage-adapted first-line treatment in the randomized GHSG HD7 to HD15 studies was investigated. Treatment consisted of radiotherapy alone, chemotherapy alone, or combined-modality approaches. RESULTS: The median age at NLPHL diagnosis was 39 years (range, 16 to 75 years). Patients were mostly male (75.8%). The median observation time was 9.2 years. At 10 years, progression-free survival and overall survival estimates were 75.5% and 92.1% (early stages, 79.7% and 93.3%; intermediate stages, 72.1% and 96.2%; advanced stages, 69.8% and 87.4%), respectively. A total of 48 patients (10.2%) developed a second malignancy during follow-up (non-Hodgkin lymphoma, n = 13; leukemia, n = 6; solid tumor, n = 25; unspecified malignancy, n = 4). Death occurred in 43 patients (9.1%). However, only a minority of deaths were NLPHL related (n = 10), whereas second malignancies (n = 20) and nonmalignant conditions possibly associated with radiotherapy or chemotherapy (n = 13) caused the death in the majority of patients. CONCLUSION: The overall outcome of patients with NLPHL who had received Hodgkin lymphoma-directed first-line treatment in randomized GHSG trial protocols was good. Nonetheless, treatment optimization is still necessary to reduce toxicity in standard-risk patients and to improve the prognosis in high-risk patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Eichenauer DA, Plütschow A, Fuchs M, et al. Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group. J Clin Oncol. 2019. PMID: 31626571. doi:10.1200/JCO.19.00986

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。